×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADVM – adverum biotechnologies, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADVM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/5
11:19 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
11/4
07:54 pm
advm
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/4
05:20 pm
advm
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
Low
Report
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
11/4
04:46 pm
advm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
Low
Report
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
11/4
04:39 pm
advm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
Low
Report
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
10/16
08:00 am
advm
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
Medium
Report
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
9/5
07:30 am
advm
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/4
04:05 pm
advm
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Low
Report
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Date
Time
Symbol
Company Name
Action
%Chg
8/12/2024
04:05 pm
advm
adverum biotechnologies, inc.
BEAT
Report
4.2%
adverum biotechnologies, inc.
5/9/2024
04:05 pm
advm
adverum biotechnologies, inc.
MISS
Report
-3.2%
adverum biotechnologies, inc.
11/9/2023
04:05 pm
advm
adverum biotechnologies, inc.
MISS
Report
2.9%
adverum biotechnologies, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/4
04:45 pm
advm
Form 10-Q Adverum Biotechnologies, For: Sep 30
Low
Report
Form 10-Q Adverum Biotechnologies, For: Sep 30
11/4
04:43 pm
advm
Form 8-K Adverum Biotechnologies, For: Nov 04
Low
Report
Form 8-K Adverum Biotechnologies, For: Nov 04
10/31
12:41 pm
advm
Form SCHEDULE 13G Adverum Biotechnologies, Filed by: FRANKLIN RESOURCES INC
Low
Report
Form SCHEDULE 13G Adverum Biotechnologies, Filed by: FRANKLIN RESOURCES INC
10/30
09:35 pm
advm
Form SC 13G Adverum Biotechnologies, Filed by: Stern Augustus
Medium
Report
Form SC 13G Adverum Biotechnologies, Filed by: Stern Augustus
10/23
01:34 pm
advm
Form SC 13G Adverum Biotechnologies, Filed by: Principia Wealth Advisory, LLC
Low
Report
Form SC 13G Adverum Biotechnologies, Filed by: Principia Wealth Advisory, LLC
10/22
06:07 pm
advm
Form SC 13G Adverum Biotechnologies, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Adverum Biotechnologies, Filed by: BlackRock, Inc.
8/12
04:11 pm
advm
Form 10-Q Adverum Biotechnologies, For: Jun 30
Low
Report
Form 10-Q Adverum Biotechnologies, For: Jun 30
8/12
04:09 pm
advm
Form 8-K Adverum Biotechnologies, For: Aug 12
Low
Report
Form 8-K Adverum Biotechnologies, For: Aug 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
30.8%
5/16 Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD 26.0%
2/10 Form 424B5 Adverum Biotechnologies, 23.8%
7/8 Adverum Biotechnologies to Present Data at Upcoming Conferences 22.5%
2/9 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. 21.0%
3/18 Form 4 Adverum Biotechnologies, For: Mar 17 Filed by: PATTERSON LEONE D 17.0%
10/11 Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting 15.1%
3/19 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.2%
3/25 Form 4 Adverum Biotechnologies, For: Mar 20 Filed by: PATTERSON LEONE D 9.2%
10/31 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates 8.8%
5/16 Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD 26.0%
2/10 Form 424B5 Adverum Biotechnologies, 23.8%
7/8 Adverum Biotechnologies to Present Data at Upcoming Conferences 22.5%
2/9 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. 21.0%
3/18 Form 4 Adverum Biotechnologies, For: Mar 17 Filed by: PATTERSON LEONE D 17.0%
10/11 Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting 15.1%
3/19 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.2%
3/25 Form 4 Adverum Biotechnologies, For: Mar 20 Filed by: PATTERSON LEONE D 9.2%
10/31 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates 8.8%
TOP News Decliners
3/11
Adverum Biotechnologies Announces Data Presentations at ARVO 2020
-13.8%
3/16 Adverum Biotechnologies Inc (NASDAQ: ADVM) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating on the stock. -13.2%
8/1 Adverum Biotechnologies Announces Board and Senior Management Changes -12.6%
2/10 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock, up previously from $10.00. -11.8%
4/20 Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors -11.6%
3/5 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update -10.7%
9/13 Adverum Biotechnologies Inc (NASDAQ: ADVM) had its price target lowered by analysts at Chardan Capital from $10.00 to $6.00. They now have a "neutral" rating on the stock. -10.4%
4/29 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
3/11 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -9.4%
3/2 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM -9.1%
3/16 Adverum Biotechnologies Inc (NASDAQ: ADVM) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating on the stock. -13.2%
8/1 Adverum Biotechnologies Announces Board and Senior Management Changes -12.6%
2/10 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock, up previously from $10.00. -11.8%
4/20 Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors -11.6%
3/5 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update -10.7%
9/13 Adverum Biotechnologies Inc (NASDAQ: ADVM) had its price target lowered by analysts at Chardan Capital from $10.00 to $6.00. They now have a "neutral" rating on the stock. -10.4%
4/29 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
3/11 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -9.4%
3/2 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM -9.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: